Canada markets open in 1 hour 38 minutes

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.03-0.52 (-1.22%)
At close: 04:00PM EDT
42.03 0.00 (0.00%)
Pre-Market: 06:12AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close42.55
Open42.58
Bid42.76 x 900
Ask43.40 x 1100
Day's Range41.97 - 42.78
52 Week Range32.87 - 54.44
Volume853,933
Avg. Volume1,229,423
Market Cap6.126B
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-2.56
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.75
  • Insider Monkey

    30 Biggest Biotechnology Companies in the World

    In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]

  • Zacks

    Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

    Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.

  • PR Newswire

    Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

    Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH). The study met its primary endpoint at both doses (120 mg and 90 mg), achieving liver histologic improvement, and also met the important secondary endpoint of MASH resolution.